Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xtandi March-In Fight Extended to Paxlovid, Insulin, HIV, Asthma And Hepatitis C Drugs

Executive Summary

In drug pricing move, Public Citizen and others petition HHS Secretary Becerra to use government authorities to get generic versions of six drugs on the market before patent expiration.

You may also be interested in...



Viatris Wins First US Symbicort Generic – Will It Launch At Risk?

In the wake of a favorable US Court of Appeals for the Federal Circuit decision, Viatris has won FDA approval for the first generic Symbicort product. The ANDA sponsor’s management had recently declared itself “ready to launch if the opportunity presents itself in 2022.”

Xtandi Petition Will Give Biden Administration Chance To Weigh In On Pricing, March-In Rights

Prostate cancer patients press HHS for administrative hearing on march-in rights for patents covering Astellas’ Xtandi. While previous efforts have failed, petitioners believe they may have a shot this time around given Biden Administration and HHS Secretary Becerra’s views on the issue.

End Of The 'March-In' Pricing Petitions?

KEI vows to continue battle over Bayh-Doyle restrictions after US Commerce Department suggests it may issue regulations to exclude pricing as a basis for requiring companies to license their patents.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel